Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
| ▸ | MAT2A | P31153 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | CDC7 | O00311 | 1/20 | 0.44 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.44 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | GRM6 | O15303 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5650867 | 0.95 | MAPT (0.47) | MAPTALDH1A1MEN1KMT2AGAA | |
| SCHEMBL5653998 | 0.95 | MAPT (0.48) | MAPTALDH1A1MEN1KMT2AGAA | |
| SCHEMBL5652595 | 0.94 | MAPT (0.45) | MAPTALDH1A1MEN1KMT2AGAA | |
| SCHEMBL5652764 | 0.94 | MAPT (0.45) | MAPTALDH1A1MEN1KMT2AGAA | |
| SCHEMBL5652293 | 0.93 | MAPT (0.44) | MAPTALDH1A1MEN1KMT2AGAA | |
| SCHEMBL5652325 | 0.93 | MAPT (0.47) | MAPTALDH1A1MEN1KMT2AGAA | |
| SCHEMBL5647395 | 0.93 | MAPT (0.50) | MAPTALDH1A1MEN1KMT2AGAA | |
| SCHEMBL5648531 | 0.93 | ALDH1A1 (0.47) | MAPTALDH1A1MEN1KMT2AGAA | |
| SCHEMBL5652346 | 0.93 | MAPT (0.47) | MAPTALDH1A1MEN1KMT2AGAA | |
| SCHEMBL5652339 | 0.93 | MAPT (0.44) | MAPTALDH1A1MEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7176215-B2 | Bicyclic oxopyridine and oxopyrimidine derivatives | CELLTECH R&D LIMITED (GB) | 2007-02-13 | — | — | US | claimed |
| US-20050059681-A1 | Far field light microscopical method system and computer program product for analysing at least one object having a subwavelength size | RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG (DE) | 2005-03-17 | — | — | US | claimed |
| US-20040254200-A1 | Bicyclic oxopyridine and oxopyrimidine derivatives | UCB PHARMA S.A. (BE) | 2004-12-16 | — | — | US | claimed |
| US-7176215-B2 | Bicyclic oxopyridine and oxopyrimidine derivatives | CELLTECH R&D LIMITED (GB) | 2007-02-13 | — | — | US | disclosed |
| US-20040254200-A1 | Bicyclic oxopyridine and oxopyrimidine derivatives | UCB PHARMA S.A. (BE) | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059681-A1 | Far field light microscopical method system and computer program product for analysing at least one object having a subwavelength size | CFL1, INF2, COG6 | MAPT 2130/4885ALDH1A1 2400/4885MEN1 621/4885 |
| US-20040254200-A1 | Bicyclic oxopyridine and oxopyrimidine derivatives | MAPK1, ALK, NAT1 | MAPT 3795/4885ALDH1A1 1498/4885MEN1 4697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.